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We would like to congratulate Drs. Antin et al. on their
thorough and practical review of mixed chimerism after
hematopoietic stem cell transplantation (HSCT) [1]. We
agree that frequent measurements of hematopoietic
chimerism are warranted after transplantation. We also
agree with the recommendation to use more accurate vari-
able number tandem repeats (VNTR) or short tandem
repeats (STR) analyses to evaluate hematopoietic chimer-
ism. Antin and colleagues clearly delineate the decision-
making process for malignant disease. In contrast, the levels
of mixed chimerism necessary for effective correction in the
setting of nonmalignant disease are less clear. The authors
suggest that levels of chimerism in excess of 10% are
required for correction of the nonmalignant disease pheno-
type. However, they proceed to recommend that donor lev-
els of 3% to 10% are sufﬁcient for correction in the context
of sickle cell disease (SCD).
This recommendation is at odds with recent human and
animal studies of SCD. Unfortunately, insights into the
requirements sufficient for functional correction of the
human disease phenotype have been based on studies
involving anectodatal observations in a small number of
patients undergoing matched sibling allografts after mye-
loablative chemotherapy. In this context, the lowest
reported degree of stable donor hematopoietic chimerism
found to correct SCD is approximately 11% donor cells sus-
tained over 6 years after matched sibling allograft using an
HbAA donor. The patient who underwent this treatment
has demonstrated a hemoglobin S of approximately 7% on
serial hemoglobin electrophoreses (M. Walters, personal
communication). Similar studies suggest that a higher level
of chimerism, 30% to 40%, is required if HbAS donors are
used. Elegant studies in an animal model of SCD conﬁrm
the necessity of a similar level of correction of HbS levels.
Indeed, these studies suggest that higher levels of donor
chimerism (≥20%) may be required to retard or correct the
silent organ pathology characteristic of SCD [2]. Interest-
ingly, human and animal studies of β-thalassemia, a related
hemoglobinopathy, conﬁrm the 10% threshold [3]. 
Further transplantation trials will be required to establish
a ﬁrm recommendation on the degree of donor chimerism
required for correction of the circulating HbS levels and the
organ damage inherent to this disease. Measurement of lineage-
speciﬁc chimerism will be particularly helpful in this context,
yielding more precise information than routine marrow or
peripheral blood analyses. Finally, it is possible that the use of
alternate donor grafts in SCD will make it necessary to mod-
ify the donor chimerism threshold, this threshold modiﬁca-
tion depending in part on donor source, graft engineering,
and the conditioning regimen used.
In summary, the evidence to date suggests that donor
cell engraftment of greater than 10% is required for effec-
tive treatment of patients with sickle cell disease in the con-
text of hemoglobin AA donors. A similar level is required
for treatment of β-thalassemia. Levels of donor hemato-
poietic chimerism perhaps as high as 30% to 40% may be
required for SCD patients with hemoglobin AS donors. 
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